The post the stablecoin receives an A rating appeared on BitcoinEthereumNews.com. In the ever-evolving landscape of decentralized finance (DeFi), the search forThe post the stablecoin receives an A rating appeared on BitcoinEthereumNews.com. In the ever-evolving landscape of decentralized finance (DeFi), the search for

the stablecoin receives an A rating

In the ever-evolving landscape of decentralized finance (DeFi), the search for secure, transparent, and truly decentralized stablecoins has become a priority for both institutional and private users.

In this context, BOLD, the stablecoin pegged to the US dollar developed by Liquity, has distinguished itself by receiving an A- rating from Bluechip, the independent rating agency specializing in stablecoins.

This achievement places BOLD at the top among stablecoins fully backed by crypto-native collateral, surpassing well-known names like USDC and DAI, both rated B+.

Bluechip Evaluation: Rigorous Criteria and Transparency

Bluechip serves as a benchmark for evaluating stablecoins, applying stringent criteria that include stability, management, decentralization, and governance. The rating obtained by BOLD reflects perfect scores (1.0) in Management, Decentralization, and Governance, placing it among the best stablecoins analyzed to date and on par with PayPal’s stablecoin, PYUSD.

Bluechip’s methodology focuses on key elements such as collateral quality, peg maintenance mechanisms, risk management, and governance structure.

The goal is to provide users and institutions with reliable tools to understand the differences between various stablecoin models, especially at a time when these represent the backbone infrastructure of the crypto and DeFi markets.

BOLD: Decentralization and Security Without Compromise

What makes BOLD unique in its kind is its complete decentralization and the absence of counterparty risks. The stablecoin is exclusively backed by Ethereum-native assets, such as ETH and the main liquid staking tokens (wstETH and rETH), without relying on banks, custodians, or off-chain reserves. This approach eliminates the risk of discretionary interventions and offers users a transparent and predictable alternative.

The BOLD protocol operates through immutable smart contracts, devoid of administrative keys and without the ability to freeze or blacklist funds.

All minting and redemption operations are accessible to anyone, at any time, and the stablecoin is always redeemable for the equivalent of 1 dollar in underlying collateral. The level of overcollateralization exceeds 200%, ensuring solid coverage even in adverse market conditions.

A Model Without Governance and Risks of Arbitrary Modification

Unlike many centralized or semi-centralized stablecoins, BOLD eliminates any form of discretionary governance. There are no committees, administrators, or intermediaries capable of altering the protocol’s rules. This means that users can rely on a system with clear, immutable, and on-chain verifiable rules in real-time.

According to Michael Svoboda, founder of Liquity Protocol, “BOLD is designed so that users do not have to rely on issuers, banks, or governance committees, but only on code. The A- rating with perfect scores for decentralization and governance demonstrates that a crypto-native stablecoin can meet institutional risk standards without depending on centralized intermediaries.”

An Alternative for Institutions and Advanced Users

The architecture of BOLD is specifically designed for DeFi treasuries, funds, and experienced users who wish to diversify their exposure to stablecoins with a truly sovereign and crypto-native asset.

Total transparency, the absence of blacklists, and the ability to verify every transaction directly on the blockchain make BOLD an ideal choice for those seeking control, transparency, and predictable rules.

Liquity V2, the new version of the protocol, distributes 100% of the revenue directly to BOLD users through a native model, without lending users’ collateral and allowing full withdrawals at any time. This structure eliminates the risk of arbitrary changes to economic rules, providing long-term operational certainty.

The Liquity Experience: From LUSD to BOLD

Liquity is not new to the decentralized stablecoin sector. The team has already developed LUSD, one of the longest-standing and most reliable stablecoins, which has reached a total value locked of $5 billion and has operated for over four years without security incidents.

BOLD represents the second generation of Liquity-branded stablecoins, expanding the principles of immutability and governance-free operation with greater capital efficiency and extended functionalities.

The Role of Independent Ratings in the Future of Stablecoins

With the growing global debate on regulation and transparency of stablecoins, independent assessments like those from Bluechip are becoming essential tools for risk management. Bluechip, established after the collapse of Terra/LUNA in 2022, applies a rating system ranging from A+ to F and has demonstrated remarkable accuracy: 75% of stablecoins rated F subsequently lost their peg.

The A- rating of BOLD demonstrates that decentralized and crypto-native stablecoins can achieve the highest levels of security, offering an inherently more prudent risk profile compared to bank-backed alternatives.

Conclusions: BOLD Marks a New Milestone for DeFi

The rise of BOLD as the benchmark stablecoin for transparency, decentralization, and security marks a significant step for the entire DeFi ecosystem. In a sector where trust in code and on-chain transparency is crucial, BOLD establishes itself as a reference model for those seeking stability without compromises and without relying on centralized intermediaries.

For more information on Liquity and BOLD, you can visit the official website [liquity.org](https://www.liquity.org).

Source: https://en.cryptonomist.ch/2026/01/26/bold-surpasses-usdc-and-dai-the-defi-stablecoin-receives-an-a-rating-from-bluechip/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26